Archana Vijayakumar

机构：Mahatma Gandhi University, University of Dundee, Meta (United States), Clinical Trials New Zealand, SUPERA Park of Innovation and Technology of Ribeirão Preto, Gastroenterology Center of Connecticut

发表论文 68 篇 · 总被引 2925 次 · h-index 22

代表论文

• ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH (2024 · Journal of Hepatology · 被引 31)
• An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial (2026 · Nature Medicine · 被引 3)
• Harnessing visible light for alkenylation reactions: A promising strategy in organic synthesis (2025 · Molecular Catalysis · 被引 3)
• Abstract 12564: Safety, Pharmacokinetics, and Lipid Lowering Effects of the Oral, Liver-Targeted Liver X Receptor (LXR) Inverse Agonist TLC-2716 in Healthy Volunteers (2023 · Circulation · 被引 3)
• Recent Advances in Visible Light‐Promoted Ring Opening of Aryl Cyclopropanes (2025 · ChemistrySelect · 被引 2)
• 899-P: Combinations of the Mitochondrial Protonophore TLC-6740 and/or the ACC2 Inhibitor TLC-3595 Provide Additive Glycemic Benefits to Semaglutide (SEMA) in db/db Mice (2024 · Diabetes · 被引 2)